A user is using a topical treatment called Formula 82f, which contains finasteride, minoxidil, and a steroid, along with Ketoconazole shampoo for hair loss. They are considering whether to switch to oral medication for better results.
Upcoming hair loss treatments for those who can't tolerate DHT blockers, focusing on Minoxidil, microneedling, and ketoconazole. Promising treatments include GT20029, PP405, KX-826, and RU58841, though RU58841 may not be safe.
A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.
The user used finasteride but stopped due to side effects, then used topical minoxidil for 13 months, and later added KX826/pyrilutamide for 8 months. They experienced shedding after starting pyrilutamide and use minoxidil and KX826 once daily.
Biotin can cause cystic acne for some users, and it's advised to stop using it if this occurs. For hair loss, finasteride and dutasteride are recommended, but a dermatologist should be consulted.
A 23-year-old male with slight hair thinning is using ketoconazole shampoo, biotin, zinc, magnesium, D3/K2, and has just started topical finasteride (0.0125%). He plans to add minoxidil (4.5%) with 17α-estradiol and is seeking advice on the effectiveness and side effects of these treatments, as well as the use of a dermaroller.
A user experienced an allergic reaction, including swollen lymph nodes, to Minoxidil 5% with an aqueous base. Switching to a non-alcohol-based Minoxidil (Prolox 5%) resolved the allergies.
Concerns about the potential high cost of new hair loss treatments, pp405 and gt20029, were discussed, with some users willing to pay a premium if they are effective. Alternatives like finasteride and minoxidil are mentioned as current, more affordable options, and there is speculation about future generic versions and black market availability.
Minoxidilmax offering a 0.5% Pyrilutamide solution and debating the cost, effectiveness, and safety of using it alone or with other treatments such as Finasteride and Minoxidil.
The user has been using topical minoxidil 6% and finasteride 0.05% once daily, along with microneedling, vitamins, and nizoral shampoo. They recently increased the topical treatments to twice daily for faster results, experiencing only initial shedding.
The user is experiencing severe hair thinning and is using multiple treatments including topical finasteride, minoxidil, tretinoin, latanoprost, oral minoxidil, dutasteride, saw palmetto, and derma wounding. They are considering adding RU58841 and are contemplating a hair transplant and exosomes due to frustration with current results.
Minoxidil 0.5% MMP® showed better results in parietal-vertex regions for less advanced female pattern hair loss compared to Minoxidil 5%. MMP® with Minoxidil can improve the quality of life for these patients.
Sodium dodecyl sulfate, oleic acid, and palmitoleic acid may promote hair growth, but their safety and effectiveness for humans are uncertain. Users consider trying these treatments cautiously, exploring alternatives like ostrich oil and microneedling.
Bimatoprost and latanoprost are being considered for scalp hair growth, with concerns about side effects like skin darkening and fat loss. A user warns about potential chemical burns from latanoprost.
Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.
A 30 year-old male's 8 month progress with hair loss treatments, including minoxidil, finasteride, microneedling, scalp massage, and ketoconazole. Another user mentioned the shed being significant.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
The user has been using minoxidil daily, finasteride three times a week, and ketoconazole 1-3 times a week for a year to treat hair loss, resulting in noticeable hair regrowth at the hairline and temples, with minor side effects like itching and dandruff. They started with minoxidil a month before the other treatments and experienced an initial shedding phase for about six weeks.
Carnosic acid in rosemary extract may enhance skin repair and promote hair follicle regeneration. It could be used alone or with verteporfin for scarless healing after dermal wounding.
A user experiencing scalp pain and diffuse hair thinning is taking finasteride and using Nizoral shampoo. They plan to continue finasteride for 6 months and consider adding minoxidil if no improvement is seen.
A user's positive early results after 2.5 months of using a topical finasteride/minoxidil spray and Nizoral twice a week for hair loss. The user, who started losing hair six years ago at age 22, is asked to share further progress at the six-month mark.
PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.
The conversation discusses hair loss treatments, including finasteride, Nizoral shampoo, peppermint/castor oil with saw palmetto, and plans to start oral minoxidil. The user seeks advice on managing scalp buildup and flakiness from topical minoxidil, especially for curly hair, and considers using both oral and topical minoxidil.
The conversation humorously acknowledges the role of mice in testing Minoxidil for hair loss while also discussing the ethics of animal testing. Some users argue against animal testing, citing cruelty, while others defend its necessity for medical advancements.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
Clascoterone, an acne treatment that blocks DHT, is being developed for scalp use against hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.